Voyager Therapeutics (VYGR) Amortizatization of Intangibles (2015 - 2026)
Voyager Therapeutics (VYGR) posted Amortizatization of Intangibles of $365000.0 for Q1 2026, down 31.13% sequentially from $530000.0 in Q4 2025, and down 63.43% YoY from $998000.0 in Q1 2025.
Voyager Therapeutics (VYGR) Amortizatization of Intangibles (2015 - 2026) Analysis & Trends
Voyager Therapeutics has reported Amortizatization of Intangibles for 12 years, with the latest figure at $365000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 63.43% year-over-year to $365000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 66.74% YoY) and the FY2025 annual result came in at $3.0 million, down 62.69% from the prior year.
- Amortizatization of Intangibles slipped to $365000.0 in Q1 2026 per VYGR's latest filing, from $530000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2.5 million in Q2 2024 and troughed at -$21000.0 in Q1 2022.
- A 5-year average of $879352.9 and a median of $654000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles soared 30700.0% in 2024, then plunged 68.27% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at -$7000.0 in 2022, then surged by 25728.57% to $1.8 million in 2023, then fell by 15.66% to $1.5 million in 2024, then plunged by 64.97% to $530000.0 in 2025, then sank by 31.13% to $365000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $365000.0, $530000.0, and $654000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Voyager Therapeutics | 205.86 Mn | 89.52 Mn | - | 1.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248,000.00 |
| Jun 30, 2026 | 248,000.00 |
| Mar 31, 2026 | 365,000.00 |
| Mar 31, 2026 | 365,000.00 |
| Dec 31, 2025 | 530,000.00 |
| Dec 31, 2025 | 530,000.00 |
| Sep 30, 2025 | 654,000.00 |
| Sep 30, 2025 | 654,000.00 |
| Jun 30, 2025 | 791,000.00 |
| Jun 30, 2025 | 791,000.00 |
| Mar 31, 2025 | 998,000.00 |
| Mar 31, 2025 | 998,000.00 |
| Dec 31, 2024 | 1.51 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 2.06 Mn |
| Sep 30, 2024 | 2.06 Mn |
| Jun 30, 2024 | 2.46 Mn |
| Jun 30, 2024 | 2.46 Mn |
| Mar 31, 2024 | 1.93 Mn |
| Mar 31, 2024 | 1.93 Mn |